A single-arm, open-label, phase II study to evaluate the safety of vemurafenib (VEM) followed by ipilimumab (IPI) in BRAF V600-mutated metastatic melanoma (MM).

Abstract

9032 Background: There is much interest in determining how to incorporate BRAF inhibitors with immune checkpoint inhibitors in the treatment of patients (pts) with BRAF-mutant MM. A phase I study s...